AU2009280843B2 - Therapeutic compositions containing macitentan - Google Patents

Therapeutic compositions containing macitentan Download PDF

Info

Publication number
AU2009280843B2
AU2009280843B2 AU2009280843A AU2009280843A AU2009280843B2 AU 2009280843 B2 AU2009280843 B2 AU 2009280843B2 AU 2009280843 A AU2009280843 A AU 2009280843A AU 2009280843 A AU2009280843 A AU 2009280843A AU 2009280843 B2 AU2009280843 B2 AU 2009280843B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
acceptable salts
diphenylpyrazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009280843A
Other languages
English (en)
Other versions
AU2009280843A1 (en
Inventor
Martine Clozel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41346591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009280843(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AU2009280843A1 publication Critical patent/AU2009280843A1/en
Application granted granted Critical
Publication of AU2009280843B2 publication Critical patent/AU2009280843B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2009280843A 2008-08-13 2009-08-12 Therapeutic compositions containing macitentan Active AU2009280843B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2008/053252 2008-08-13
IB2008053252 2008-08-13
PCT/IB2009/053553 WO2010018549A2 (en) 2008-08-13 2009-08-12 Therapeutic compositions containing macitentan

Publications (2)

Publication Number Publication Date
AU2009280843A1 AU2009280843A1 (en) 2010-02-18
AU2009280843B2 true AU2009280843B2 (en) 2015-03-05

Family

ID=41346591

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009280843A Active AU2009280843B2 (en) 2008-08-13 2009-08-12 Therapeutic compositions containing macitentan

Country Status (30)

Country Link
US (3) US8809334B2 (enExample)
EP (2) EP3300729B1 (enExample)
JP (3) JP5764061B2 (enExample)
KR (1) KR101678699B1 (enExample)
CN (1) CN102099026B (enExample)
AR (1) AR073031A1 (enExample)
AU (1) AU2009280843B2 (enExample)
BR (1) BRPI0917661B8 (enExample)
CA (1) CA2731370C (enExample)
CY (2) CY1119826T1 (enExample)
DK (2) DK3300729T3 (enExample)
ES (2) ES2763176T3 (enExample)
HK (1) HK1253355B (enExample)
HR (2) HRP20171917T1 (enExample)
HU (2) HUE047767T2 (enExample)
IL (1) IL211143A0 (enExample)
LT (2) LT3300729T (enExample)
MA (1) MA32614B1 (enExample)
MX (1) MX350011B (enExample)
MY (1) MY178894A (enExample)
NO (1) NO2315587T3 (enExample)
NZ (1) NZ591601A (enExample)
PL (2) PL3300729T3 (enExample)
PT (2) PT2315587T (enExample)
RU (1) RU2519161C2 (enExample)
SI (2) SI3300729T1 (enExample)
SM (2) SMT201900740T1 (enExample)
TW (1) TWI446911B (enExample)
WO (1) WO2010018549A2 (enExample)
ZA (1) ZA201101900B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006290309B2 (en) 2005-09-12 2012-04-05 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyrimidine-sulfamide
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
JP5522030B2 (ja) 2008-02-28 2014-06-18 日本新薬株式会社 線維化抑制剤
NO2315587T3 (enExample) 2008-08-13 2018-03-24
JP6542128B2 (ja) 2013-01-11 2019-07-10 コルセア ファーマ インコーポレイテッド トレプロスチニルのプロドラッグ
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9794795B1 (en) 2016-04-29 2017-10-17 Corning Optical Communications Wireless Ltd Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS
JP2020502121A (ja) 2016-12-14 2020-01-23 レスピラ セラピューティクス インコーポレイテッドＲｅｓｐｉｒａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 肺高血圧症および他の肺障害の処置のための方法および組成物
AU2019339401B9 (en) * 2018-09-14 2022-11-03 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
BR112021011999A2 (pt) * 2018-12-21 2021-09-08 Actelion Pharmaceuticals Ltd Composição farmacêutica para o tratamento de hipertensão arterial pulmonar
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
US12485119B2 (en) 2019-11-29 2025-12-02 Actelion Pharmaceuticals Ltd Methods of treating pulmonary arterial hypertension
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
CA3240614A1 (en) 2021-12-31 2023-07-06 Stuart Rich Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017993A1 (en) * 2002-08-12 2004-03-04 Actelion Pharmaceuticals Ltd Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539333A (en) * 1976-05-11 1985-09-03 Burroughs Wellcome Co. Prostacyclin, methods of using and method of making
DE2845770A1 (de) * 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
US4683330A (en) 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
PT1345920E (pt) * 2000-12-18 2006-08-31 Actelion Pharmaceuticals Ltd Novas sulfonamidas e sua utilizacao como antagonistas dos receptores de endotelina
CN1481244A (zh) * 2000-12-19 2004-03-10 Ĭ��ר���ɷ����޹�˾ 含有吡唑并[4,3-d]嘧啶和抗血栓形成剂、钙拮抗剂、前列腺素或前列腺素衍生物的药物制剂
DE10100426B4 (de) 2001-01-08 2006-04-06 Steag Hamatech Ag Verfahren und Vorrichtung zum Zusammenfügen von Substraten
TWI316055B (enExample) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
BR0316724A (pt) * 2002-12-02 2005-10-18 Actelion Pharmaceuticals Ltd Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
TW200628467A (en) * 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
AU2006290309B2 (en) * 2005-09-12 2012-04-05 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
US8541433B2 (en) * 2008-02-20 2013-09-24 Actelion Pharmaceuticals, Ltd. Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
NO2315587T3 (enExample) 2008-08-13 2018-03-24

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017993A1 (en) * 2002-08-12 2004-03-04 Actelion Pharmaceuticals Ltd Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIDHARTA, P.N. et al Journal of Clinical Pharmacology, Vol. 47, page 1202, Abstract 85. September 2007 *

Also Published As

Publication number Publication date
MY178894A (en) 2020-10-21
SMT201900740T1 (it) 2020-01-14
PL3300729T3 (pl) 2020-04-30
MX350011B (es) 2017-08-22
BRPI0917661A2 (pt) 2015-12-01
JP2015180683A (ja) 2015-10-15
JP2011530581A (ja) 2011-12-22
CN102099026A (zh) 2011-06-15
BRPI0917661B1 (pt) 2019-12-17
EP3300729B1 (en) 2019-10-09
BRPI0917661B8 (pt) 2021-05-25
SI2315587T1 (en) 2018-04-30
US20110136818A1 (en) 2011-06-09
US9173881B2 (en) 2015-11-03
EP3300729A1 (en) 2018-04-04
ES2763176T3 (es) 2020-05-27
US20160022678A1 (en) 2016-01-28
EP2315587B1 (en) 2017-10-25
US20140329824A1 (en) 2014-11-06
PL2315587T3 (pl) 2018-03-30
HRP20192204T1 (hr) 2020-03-06
MA32614B1 (fr) 2011-09-01
HK1253355B (en) 2020-06-19
HUE047767T2 (hu) 2020-05-28
KR20110045006A (ko) 2011-05-03
HRP20171917T1 (hr) 2018-02-09
CY1122641T1 (el) 2021-03-12
JP5956025B2 (ja) 2016-07-20
US8809334B2 (en) 2014-08-19
DK2315587T3 (en) 2018-01-02
JP2015187148A (ja) 2015-10-29
WO2010018549A2 (en) 2010-02-18
JP5764061B2 (ja) 2015-08-12
AU2009280843A1 (en) 2010-02-18
AR073031A1 (es) 2010-10-06
NO2315587T3 (enExample) 2018-03-24
HUE036071T2 (hu) 2018-06-28
DK3300729T3 (da) 2020-01-20
ZA201101900B (en) 2012-08-29
CY1119826T1 (el) 2018-06-27
EP2315587A2 (en) 2011-05-04
PT3300729T (pt) 2020-01-20
MX2011001625A (es) 2011-03-29
CA2731370A1 (en) 2010-02-18
HK1253355A1 (en) 2019-06-14
TWI446911B (zh) 2014-08-01
IL211143A0 (en) 2011-04-28
US9597331B2 (en) 2017-03-21
KR101678699B1 (ko) 2016-11-23
RU2519161C2 (ru) 2014-06-10
CN102099026B (zh) 2012-08-29
CA2731370C (en) 2017-03-14
LT3300729T (lt) 2020-01-10
RU2011109084A (ru) 2012-09-20
LT2315587T (lt) 2018-01-10
JP5956026B2 (ja) 2016-07-20
TW201010985A (en) 2010-03-16
SMT201700592T1 (it) 2018-03-08
PT2315587T (pt) 2018-01-31
SI3300729T1 (sl) 2020-02-28
WO2010018549A3 (en) 2010-07-29
NZ591601A (en) 2012-12-21
ES2652590T3 (es) 2018-02-05

Similar Documents

Publication Publication Date Title
AU2009280843B2 (en) Therapeutic compositions containing macitentan
US6312717B1 (en) Method for treatment of anxiety and depression
CN115666570A (zh) 瑞德西韦治疗方法
JP2021519764A (ja) 線維性疾患を処置する方法
HK1157221A (en) Therapeutic compositions containing macitentan
HK1157221B (en) Therapeutic compositions containing macitentan
AU2019365117A1 (en) Sildenafil for use in the treatment of osteoarthritis
US7439270B2 (en) Drugs for spinal anesthesia
EP4225771A1 (en) Compositions for inducing urinary voiding and defecation
JP2002326957A (ja) 慢性閉塞性肺疾患の治療方法
KR20050092519A (ko) 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)